<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10349R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006510</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology/Cell Signaling</subject><subject>Immunology/Cellular Microbiology and Pathogenesis</subject><subject>Immunology/Innate Immunity</subject><subject>Infectious Diseases/Tropical and Travel-Associated Diseases</subject></subj-group></article-categories><title-group><article-title>Malarial Hemozoin Is a Nalp3 Inflammasome Activating Danger Signal</article-title><alt-title alt-title-type="running-head">Hemozoin and the Inflammasome</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dostert</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guarda</surname><given-names>Greta</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Romero</surname><given-names>Jackeline F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Menu</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Olaf</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tardivel</surname><given-names>Aubry</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Suva</surname><given-names>Mario-Luca</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stehle</surname><given-names>Jean-Christophe</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kopf</surname><given-names>Manfred</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stamenkovic</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Corradin</surname><given-names>Giampietro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tschopp</surname><given-names>Jurg</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Biochemistry, University of Lausanne, Epalinges, Switzerland</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Division of Experimental Pathology, Institute of Pathology, CHUV, Lausanne, Switzerland</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Institut Integrative Biologie, ETH, Z&#x000fc;rich, Switzerland</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">New York University School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>jurg.tschopp@unil.ch</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: CD GG JCR IS GC JT. Performed the experiments: CD GG JCR PM OG AT MLS JCS. Analyzed the data: CD GG JCR. Contributed reagents/materials/analysis tools: MK. Wrote the paper: CD.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>4</day><month>8</month><year>2009</year></pub-date><volume>4</volume><issue>8</issue><elocation-id>e6510</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Dostert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Characteristic symptoms of malaria include recurrent fever attacks and neurodegeneration, signs that are also found in patients with a hyperactive Nalp3 inflammasome. <italic>Plasmodium</italic> species produce a crystal called hemozoin that is generated by detoxification of heme after hemoglobin degradation in infected red blood cells. Thus, we hypothesized that hemozoin could activate the Nalp3 inflammasome, due to its particulate nature reminiscent of other inflammasome-activating agents.</p></sec><sec><title>Methodology/Principal Findings</title><p>We found that hemozoin acts as a proinflammatory danger signal that activates the Nalp3 inflammasome, causing the release of IL-1&#x003b2;. Similar to other Nalp3-activating particles, hemozoin activity is blocked by inhibiting phagocytosis, K<sup>&#x0002b;</sup> efflux and NADPH oxidase. <italic>In vivo</italic>, intraperitoneal injection of hemozoin results in acute peritonitis, which is impaired in Nalp3-, caspase-1- and IL-1R-deficient mice. Likewise, the pathogenesis of cerebral malaria is dampened in Nalp3-deficient mice infected with <italic>Plasmodium berghei</italic> sporozoites, while parasitemia remains unchanged.</p></sec><sec><title>Significance/Conclusions</title><p>The potent pro-inflammatory effect of hemozoin through inflammasome activation may possibly be implicated in plasmodium-associated pathologies such as cerebral malaria.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Malaria infects 300&#x02013;500 million and kills more than one million children annually. The causative agents of malaria, <italic>Plasmodium</italic> species, go through a complex life cycle, involving both a mosquito vector and the human host <xref ref-type="bibr" rid="pone.0006510-Silvie1">&#x0005b;1&#x0005d;</xref>. In infected individuals the parasite first enters the clinically silent &#x0201c;liver stage&#x0201d; followed by a &#x0201c;blood stage&#x0201d;, which is characterized by cyclic red blood cell lysis resulting in fever peaks, chills and anemia <xref ref-type="bibr" rid="pone.0006510-Idro1">&#x0005b;2&#x0005d;</xref>. In less than 1&#x02013;2&#x00025; of cases, severe malaria can evolve to its most lethal form, cerebral malaria (CM). <italic>Plasmodium</italic> infection elicits in its host an immune response that is characterized mostly by IFN&#x003b3; producing T cells and antibodies directed against infected red blood cells <xref ref-type="bibr" rid="pone.0006510-Beeson1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Langhorne1">&#x0005b;4&#x0005d;</xref>. However, the immune response is also critically involved in the pathogenesis of severe malaria, largely through the overproduction of pro-inflammatory cytokines <xref ref-type="bibr" rid="pone.0006510-Schofield1">&#x0005b;5&#x0005d;</xref>. Concerning innate immunity, several conserved molecular structures of <italic>Plasmodium</italic> have been proposed to act as pathogen-associated molecular patterns (PAMPs) and are activating Toll-like receptors (TLRs) on macrophages and dendritic cells (DCs), such as glycosylphosphatidylinositol (GPI), which is a TLR2 ligand <xref ref-type="bibr" rid="pone.0006510-Coban1">&#x0005b;6&#x0005d;</xref>.</p><p>Hemozoin is a heme crystal, which is formed by the parasite in order to detoxify free heme resulting from hemoglobin digestion in the infected red blood cells <xref ref-type="bibr" rid="pone.0006510-Egan1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Hanscheid1">&#x0005b;8&#x0005d;</xref>. <italic>Plasmodium</italic> spp are able to form insoluble hemozoin crystals in order to protect themselves from oxidative damage resulting from the presence of free heme. During red blood cell lysis, hemozoin is released into the blood stream together with the parasite and cellular debris. Purified hemozoin from <italic>P. falciparum</italic>, as well as synthetic hemozoin, can activate macrophages and DCs to produce pro-inflammatory cytokines and chemokines <xref ref-type="bibr" rid="pone.0006510-Jaramillo1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Coban2">&#x0005b;10&#x0005d;</xref>. However, there are conflicting reports on the immunomodulatory capacities of hemozoin crystals <italic>per se</italic>. Hemozoin was reported to activate TLR9 signalling, and according to that TLR9- and MyD88-deficient mice were shown to be less susceptible to CM <xref ref-type="bibr" rid="pone.0006510-Coban2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Coban3">&#x0005b;11&#x0005d;</xref>. Yet these results were recently questioned <xref ref-type="bibr" rid="pone.0006510-Togbe1">&#x0005b;12&#x0005d;</xref>, as signalling triggered by <italic>P. falciparum</italic>-derived hemozoin was shown to be dependent on the presence of malarial DNA complexed to hemozoin, hence explaining the reported implication of TLR9 <xref ref-type="bibr" rid="pone.0006510-Parroche1">&#x0005b;13&#x0005d;</xref>.</p><p>The pro-inflammatory cytokines IL-1&#x003b2; and IL-18 are produced by cleavage of the inactive proIL-1&#x003b2; and proIL-18 precursors by caspase-1. Caspase-1 is activated within a large multi-protein complex, termed the inflammasome <xref ref-type="bibr" rid="pone.0006510-Martinon1">&#x0005b;14&#x0005d;</xref>, which is triggered by several danger-, stress- and/or infection-associated signals leading to caspase-1 cleavage and activation. The Nalp3 inflammasome, composed of the NLR protein Nalp3, the adaptor ASC and caspase-1, has been shown to be implicated in the production of mature IL-1&#x003b2;. It is now generally accepted that activation and release of IL-1&#x003b2; requires two distinct signals: the first signal leads to the transcriptional upregulation and synthesis of proIL-1&#x003b2; and other components necessary for inflammasome function, such as Nalp3 itself; the second signal leads to Nalp3 inflammasome complex formation, caspase-1 activation and IL-1&#x003b2; cleavage. This signal is constituted of an ever growing number of different stimuli such as bacterial and viral PAMPs <xref ref-type="bibr" rid="pone.0006510-Shaw1">&#x0005b;15&#x0005d;</xref>, stress-associated danger signals such as ATP or MSU, and other particulate stimuli such as asbestos, silica, alum and &#x003b2;-amyloid <xref ref-type="bibr" rid="pone.0006510-Yu1">&#x0005b;16&#x0005d;</xref>, while the actual mechanism by which Nalp3 activation leads to caspase-1 cleavage remains unknown. In this study we investigated whether hemozoin could act as a Nalp3 inflammasome activating danger signal leading to IL-1&#x003b2; production.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Hemozoin induces IL-1&#x003b2; secretion in myeloid cells</title><p>In an attempt to determine more precisely the immunostimulatory capacities of hemozoin crystals, we produced synthetic hemozoin (also called &#x003b2;-hematin), which is free of malarial DNA. Bone marrow-derived macrophages (BMDMs) stimulated with hemozoin produced relatively low levels of TNF&#x003b1;, IL-6 and MIP-1&#x003b1; after 6 hours stimulation, as compared to stimulation with TLR9-activating CpG <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g001"><bold>Figure 1a</bold></xref><bold>)</bold>. On the other hand, BMDMs stimulated with hemozoin were able to robustly secrete IL-1&#x003b2; and IL-18 when primed with LPS <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g001"><bold>Figure 1b</bold></xref><bold>and <xref ref-type="supplementary-material" rid="pone.0006510.s001">Figure S1a</xref>)</bold>. In order to rule out any species- or cell type-specific effects, we tested the ability of hemozoin to induce IL-1&#x003b2; production in the human macrophage-like cell line THP1 <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g001"><bold>Figure 1c</bold></xref><bold>)</bold>, as well as in murine bone marrow-derived dendritic cells (BMDCs) <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g001"><bold>Figure 1d</bold></xref><bold>)</bold>. IL-1&#x003b2; secretion was observed in both cell types in a time- and dose-dependent manner <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g001"><bold>Figure 1c</bold></xref><bold>and <xref ref-type="supplementary-material" rid="pone.0006510.s001">Figure S1b</xref>)</bold>.</p><fig id="pone-0006510-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g001</object-id><label>Figure 1</label><caption><title>Hemozoin activates IL-1&#x003b2; secretion in murine and human macrophages and dendritic cells.</title><p>(a,b) Bone marrow derived macrophages (BMDMs) were stimulated for 6 h with 150 &#x000b5;g/ml hemozoin and 2.5 &#x000b5;g/ml CpG. Cytokines and chemokines were measured by CBA. (c) THP1 cells were stimulated for 1, 3 or 6 h with hemozoin, MSU or Nigericin and analysed by western blot. (d) Bone marrow derived dendritic cells (BMDCs) were stimulated for 6 h with hemozoin, MSU, Nigericin or CpG. Cell extracts and supernatants were analysed by western blot. Data shown are representative of three independent experiments.</p></caption><graphic xlink:href="pone.0006510.g001"/></fig></sec><sec id="s2b"><title>Hemozoin-induced IL-1&#x003b2; secretion is Nalp3 inflammasome-dependent</title><p>The Nalp3 inflammasome is implicated in the production of mature IL-1&#x003b2; and IL-18 in response to different signals among which there are several particulate stimuli, such as MSU, alum or asbestos <xref ref-type="bibr" rid="pone.0006510-Yu1">&#x0005b;16&#x0005d;</xref>. The precise mechanism of Nalp3 inflammasome activation is still poorly understood. We found that hemozoin-induced IL-1&#x003b2; secretion was blocked by the pan-caspase inhibitor z-VAD, where cleaved caspase-1 was no longer observed <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g002"><bold>Figure 2a</bold></xref><bold>)</bold> and no IL-1&#x003b2; secretion could be observed in caspase-1-deficient macrophages stimulated with hemozoin or any inflammasome activator tested <bold>(<xref ref-type="supplementary-material" rid="pone.0006510.s001">Figure S1d</xref>)</bold>. In addition to caspase-1, the inflammasome components ASC and Nalp3 were required for IL-1&#x003b2; production in response to hemozoin <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g002"><bold>Figure 2a, 2b</bold></xref><bold> and <xref ref-type="supplementary-material" rid="pone.0006510.s001">Figure S1c</xref>)</bold>. In contrast, Ipaf, another NLR protein shown to form an inflammasome responsible of IL-1&#x003b2; production in response to bacteria such as <italic>Salmonella</italic><xref ref-type="bibr" rid="pone.0006510-Sutterwala1">&#x0005b;17&#x0005d;</xref>, was not essential for hemozoin-induced IL-1&#x003b2; secretion <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g002"><bold>Figure 2b</bold></xref><bold>)</bold>. In unprimed cells hemozoin was still able to induce caspase-1 cleavage although to a lesser extent, clearly showing its potent inflammasome-activating capacities <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g002"><bold>Figure 2c</bold></xref><bold>)</bold>. Hemozoin-induced IL-1&#x003b2; production was not mediated by ATP released from dying cells as a consequence of hemozoin toxicity, as shown by the use of P2X7-deficient BMDMs <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g003"><bold>Figure 3a</bold></xref><bold>)</bold>. Likewise, uric acid crystals, that can act as an endogenous danger signal produced upon cellular stress, are not involved in hemozoin-mediated signal transmission, as inflammasome activation was not altered in the presence of uricase <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g003"><bold>Figure 3b</bold></xref><bold>)</bold>. In agreement with previous results, we found that heme, the precursor of hemozoin, does not activate caspase-1 but is toxic, as seen by PARP cleavage <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g003"><bold>Figure 3c</bold></xref><bold>)</bold>. Importantly, hemozoin treatment did not result in PARP cleavage, indicating that the hemozoin preparation used is not toxic and free of contaminating heme. In order to exclude any implication of DNA-mediated TLR9 signalling in IL-1&#x003b2; production by hemozoin as proposed <xref ref-type="bibr" rid="pone.0006510-Parroche1">&#x0005b;13&#x0005d;</xref>, we used MyD88-deficient macrophages where caspase-1 cleavage was still observed, although there was no IL-1&#x003b2; secreted as expected <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4a</bold></xref><bold>)</bold>. In addition, treatment of hemozoin with DNaseI had no effect on IL-1&#x003b2; production <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4b</bold></xref><bold>)</bold>. Chloroquine is a well-known antimalarial drug, but its exact mechanism of action in malaria treatment is still unknown. It has been shown that chloroquine can interfere with the hemozoin crystallization process in infected red blood cells <xref ref-type="bibr" rid="pone.0006510-Weissbuch1">&#x0005b;18&#x0005d;</xref>. Chloroquine is also known to block endosomal acidification, resulting in improper TLR9 signalling <xref ref-type="bibr" rid="pone.0006510-Macfarlane1">&#x0005b;19&#x0005d;</xref>. Treatment with chloroquine prior to BMDM stimulation with hemozoin had no effect on IL-1&#x003b2; production by hemozoin, MSU or nigericin at any of the different chloroquine concentrations tested <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4c</bold></xref><bold> and <xref ref-type="supplementary-material" rid="pone.0006510.s002">Figure S2</xref>)</bold>. Nevertheless, chloroquine inhibited CpG-dependent IL-6 production, whereas hemozoin-induced IL-6 and MIP-1&#x003b1; production was independent of TLR9 <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4c</bold></xref><bold> and data not shown)</bold>. We also tested the effect of bafilomycin A1 on inflammasome activation in response to hemozoin. Bafilomycin blocks the vacuolar H<sup>&#x0002b;</sup> ATPase system necessary for lysosomal acidification and has been shown to inhibit inflammasome activation in response to silica <xref ref-type="bibr" rid="pone.0006510-Hornung1">&#x0005b;20&#x0005d;</xref>. We could not observe this effect on inflammasome activation by hemozoin, MSU or nigericin both in BMDMs and in THP1 cells <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4d,e</bold></xref><bold>)</bold>. However, bafilomycin could strongly reduce proIL1&#x003b2; induction in response to stimulation with CpG <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g004"><bold>Figure 4d</bold></xref><bold>)</bold>.</p><fig id="pone-0006510-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g002</object-id><label>Figure 2</label><caption><title>Hemozoin induced IL-1&#x003b2; secretion is NALP3 inflammasome-dependent.</title><p>(a,b) BMDMs from wild-type (WT), ASC-, Nalp3- or Ipaf-deficient mice were stimulated for 6 h with hemozoin (150 &#x000b5;g/ml) or MSU (150 &#x000b5;g/ml ) in the presence of 20 &#x000b5;M z-VAD or 130 mM KCl where indicated (&#x0002a; nonspecific band). (c) BMDMs were primed or not with LPS before stimulation with hemozoin or MSU. Data shown are representative of three independent experiments.</p></caption><graphic xlink:href="pone.0006510.g002"/></fig><fig id="pone-0006510-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g003</object-id><label>Figure 3</label><caption><title>Hemozoin induced IL-1&#x003b2; production is independent from P2X7 activation.</title><p>(a) BMDMs were stimulated for 45 min with 5 mM ATP, or for 6 h with 100 &#x000b5;g/ml hemozoin and 100 &#x000b5;g/ml MSU. (b) Uricase treatment (0,1 U/ml) of THP1 cells does not affect IL-1&#x003b2; production by hemozoin. Cells were stimulated with 150 &#x000b5;g/ml hemozoin, 150 &#x000b5;g/ml asbestos and 50 &#x000b5;g/ml MSU. (c) Heme does not activate caspase-1 cleavage in BMDMs as compared to hemozoin (150 &#x000b5;g/ml) or MSU (150 &#x000b5;g/ml), but leads to PARP cleavage, indicating its toxicity. Cell supernatants and extracts were analysed by Western blot.</p></caption><graphic xlink:href="pone.0006510.g003"/></fig><fig id="pone-0006510-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g004</object-id><label>Figure 4</label><caption><title>Hemozoin induced IL-1&#x003b2; production is independent from MyD88-mediated signaling pathways.</title><p>(a) Caspase-1 activation can still be observed in MyD88-deficient BMDMs, albeit to a lesser extent. (b) BMDMs were stimulated with hemozoin, MSU and Nigericin in the presence or absence of DNaseI (100 U/ml). Cells were stimulated for 6 h with 150 &#x000b5;g/ml hemozoin, 150 &#x000b5;g/ml MSU and 1.34 &#x000b5;M Nigericin. Cell supernatants and extracts were analysed by Western blot. (c) BMDMs were stimulated with hemozoin, MSU, Nigericin or CpG (2,5 &#x000b5;g/ml) in the presence or absence of 10 &#x000b5;M chloroquine. (d,e) BMDMs (d) and THP1 cells (e) were stimulated with hemozoin, MSU, nigericin and CpG in the presence or absence of bafilomycinA1 (250 nM in (d) and 50 and 250 nM in (e)). IL-1&#x003b2; secretion and caspase-1 cleavage were analysed by western blot; IL-6 was analysed by CBA.</p></caption><graphic xlink:href="pone.0006510.g004"/></fig><p>Phagocytosis of hemozoin crystals is necessary for Nalp3 inflammasome activation as shown by the ability of cytochalasin D to suppress IL-1&#x003b2; production <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g005"><bold>Figure 5a</bold></xref><bold>)</bold>. Similar to Nalp3 inflammasome activation by other particulate stimuli such as MSU or asbestos, hemozoin-induced IL-1&#x003b2; production was inhibited by blocking the K<sup>&#x0002b;</sup> efflux from the cell by using the ATP-sensitive potassium channel inhibitor glybenclamide <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g002"><bold>Figure 2a,b</bold></xref><bold> and </bold><xref ref-type="fig" rid="pone-0006510-g005"><bold>Figure 5b</bold></xref><bold>)</bold>. Also, generation of ROS is implicated in hemozoin-induced IL-1&#x003b2; production, as demonstrated by experiments using the NADPH oxidase inhibitor DPI or cells with p22phox levels that are reduced by RNAi <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g005"><bold>Figure 5c,d</bold></xref><bold>)</bold>. The exact source of ROS is still unclear, since the gp91phox (NOX2) subunit of the complex does not seem to be required for inflammasome activation (<xref ref-type="fig" rid="pone-0006510-g005"><bold>Figure 5e</bold></xref> and <xref ref-type="bibr" rid="pone.0006510-Hornung1">&#x0005b;20&#x0005d;</xref> ). This observation suggests the implication of one of the several other NOX isoforms in this process. An additional mechanism of inflammasome activation based on lysosomal destabilisation and release of cathepsin B in response to crystal phagocytosis was recently proposed <xref ref-type="bibr" rid="pone.0006510-Hornung1">&#x0005b;20&#x0005d;</xref>. We took advantage of cathepsin B-deficient BMDMs to test this hypothesis, however no differences in IL-1&#x003b2; secretion and caspase-1 cleavage in response to several inflammasome activators, such as hemozoin, MSU or alum were observed (<xref ref-type="fig" rid="pone-0006510-g005"><bold>Figure 5f</bold></xref>). Similar results were observed in bone-marrow derived dendritic cells (<bold>data not shown</bold>).</p><fig id="pone-0006510-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g005</object-id><label>Figure 5</label><caption><title>Phagocytosis, K<sup>&#x0002b;</sup> efflux and activation of a NADPH oxidase are essential for hemozoin-mediated inflammasome activation.</title><p>(a) Crystal phagocytosis is essential for hemozoin induced IL-1&#x003b2; production as evidenced by the use of cytochalasin D (2 &#x000b5;M) to block the actin cytoskeleton. (b) Hemozoin induced IL-1&#x003b2; production can be reduced by blocking the K<sup>&#x0002b;</sup> efflux from the cells by adding high extracellular K<sup>&#x0002b;</sup> concentration to the culture medium (130 mM KCl) or by using glybenclamide, an ATP-sensitive potassium channel inhibitor (50 &#x000b5;M). (c) Hemozoin induced IL-1&#x003b2; production can be reduced by the use of ROS inhibitors, such as APDC (50 &#x000b5;M) and DPI (20 &#x000b5;M). (d) NADPH oxidase subunit p22phox is essential for inflammasome activation by hemozoin. (e) gp91phox(NOX2)-deficient BMDMs were stimulated with different crystals and nigericin for 6 h. (f) Cathepsin B-deficient BMDMs were stimulated with the indicated inflammasome activators for 6 h. THP1 cells were stimulated for 6 h with 150 &#x000b5;g/ml hemozoin, 100 &#x000b5;g/ml MSU, 100 &#x000b5;g/ml asbestos and 1,34 &#x000b5;M Nigericin. Salmonella were added to the cells at an MOI of 10. BMDMs were stimulated with 150 &#x000b5;g/ml hemozoin, 150 &#x000b5;g/ml MSU, 250 &#x000b5;g/ml silica, 150 &#x000b5;g/ml alum, 15 &#x000b5;g/ml R837 and 1,34 &#x000b5;M Nigericin Cell supernatants and extracts were analysed by Western blot.</p></caption><graphic xlink:href="pone.0006510.g005"/></fig></sec><sec id="s2c"><title>Hemozoin has pro-inflammatory properties <italic>in vivo</italic></title><p>In order to determine the pro-inflammatory and danger signal capacities of hemozoin <italic>in vivo</italic>, we used a well-established peritonitis model where intraperitoneal injection of inflammasome activators results in neutrophil influx to the peritoneal cavity <xref ref-type="bibr" rid="pone.0006510-Hornung1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Martinon2">&#x0005b;21&#x0005d;</xref>. Hemozoin elicited a considerable increase in the recruitment of neutrophils 6 h after injection compared to PBS in both mice on a C57BL/6 background (Nalp3<sup>&#x0002b;/&#x0002b;</sup>) and on a BALB/c background (IL-1R<sup>&#x0002b;/&#x0002b;</sup>) <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g006"><bold>Figure 6</bold></xref><bold>)</bold>. When hemozoin was injected in mice deficient in IL-1R, neutrophil influx was markedly impaired, implicating a role for IL-1 signalling in attracting neutrophils to the peritoneal cavity <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g006"><bold>Figure 6a</bold></xref><bold>)</bold>. In keeping with this, the IL-1 antagonist, IL-1Ra (Anakinra) also efficiently blocked neutrophil recruitment <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g006"><bold>Figure 6b</bold></xref><bold>)</bold>. Importantly, reduced neutrophil influx was also observed in caspase-1-deficient mice and Nalp3-deficient mice <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g006"><bold>Figure 6c and d</bold></xref><bold>)</bold>, as well as in ASC-deficient mice <bold>(<xref ref-type="supplementary-material" rid="pone.0006510.s003">Figure S3a</xref>)</bold>. In contrast, zymosan-induced neutrophil influx was not affected by IL-1R- or Nalp3-deficiency, indicating that Nalp3-deficient mice do not have a general defect in neutrophil recruitment <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g006"><bold>Figure 6e and f</bold></xref><bold>)</bold>. The reduction in neutrophil recruitment was strongest in IL-1R-deficient and Anakinra-treated mice, suggesting that IL-1&#x003b1; or other signalling pathways participate in hemozoin-induced neutrophil recruitment. Chloroquine treatment had no significant effect, suggesting that TLR9 is not involved in attracting neutrophils to the peritoneal cavity in response to hemozoin <bold>(<xref ref-type="supplementary-material" rid="pone.0006510.s003">Figure S3b</xref>)</bold>.</p><fig id="pone-0006510-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g006</object-id><label>Figure 6</label><caption><title>Role of the inflammasome in a mouse model of hemozoin-induced peritonitis.</title><p>(a-f) The indicated WT or mutant mice were injected intraperitoneally with 0.25 mg of hemozoin, 0.2 mg of zymosan or PBS as a control. Neutrophil influx (CD11b<sup>&#x0002b;</sup> Ly-6C<sup>&#x0002b;</sup> Ly-6G<sup>high</sup> F4/80<sup>&#x02212;</sup>) was quantified 6 h later by FACS (values are mean&#x000b1;s.e.m and <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;4&#x02013;6 mice per group). Differences between groups were calculated using the unpaired t test and were considered significant (&#x0002a;) when p&#x02264;0.05. Data shown are representative of three independent experiments.</p></caption><graphic xlink:href="pone.0006510.g006"/></fig></sec><sec id="s2d"><title>Nalp3 is implicated in the development of cerebral malaria</title><p>Based on the observed inflammasome-activating capacity of hemozoin <italic>in vitro</italic>, we investigated the potential role for the inflammasome in malaria. To this end we used <italic>Plasmodium berghei</italic> ANKA (PbA) infection in mice as a model for cerebral malaria (CM) <xref ref-type="bibr" rid="pone.0006510-Sanni1">&#x0005b;22&#x0005d;</xref>. Mice were injected intravenously with a low number of PbA sporozoites, which first migrate to the liver where they evolve to form merozoites that are released during the clinically silent liver stage. The merozoites eventually invade erythrocytes leading to their cyclic rupture and re-infection. Mice on a C57Bl/6 background are susceptible for developing the neurological signs of CM and usually die 7&#x02013;12 days post infection. When wild type (Nalp3<sup>&#x0002b;/&#x0002b;</sup>) and Nalp3-deficient mice were infected with 10 PbA sporozoites, a consistent proportion of Nalp3<sup>&#x0002b;/&#x0002b;</sup> control mice died from CM after 7&#x02013;12 days, whereas the Nalp3-deficient mice resisted better to CM development <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7a</bold></xref><bold>)</bold>. Mice from both groups were similarly infected with PbA, as parasitemia, corresponding to the percentage of infected red blood cells (iRBC), could be monitored for all the mice <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7b</bold></xref><bold>)</bold>. Increasing parasitemia was observed in both the Nalp3<sup>&#x0002b;/&#x0002b;</sup> and the Nalp3-deficient mice that resisted CM, and mice were killed three weeks after infection when their iRBC number exceeded 80&#x00025; and the mice developed hyperparasitemia-induced anaemia, a condition unrelated to CM. Overall, 73&#x00025; of Nalp3<sup>&#x02212;/&#x02212;</sup> mice were resistant to CM, as compared to only 44&#x00025; of Nalp3<sup>&#x0002b;/&#x0002b;</sup> mice <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7c</bold></xref><bold>)</bold>. We examined immunopathological changes in the brains of Nalp3<sup>&#x0002b;/&#x0002b;</sup> and Nalp3<sup>&#x02212;/&#x02212;</sup> mice 9 days after infection. Nalp3<sup>&#x0002b;/&#x0002b;</sup> mice showed typical vascular occlusion with parasitized erythrocytes as well as lymphomonocytic infiltrates and microvascular destruction including pathological endothelial cells <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7d</bold></xref> (i)<bold>)</bold>. In contrast, very limited characteristic pathological changes were detected in Nalp3-deficient mice, such as moderate leukocyte infiltration and damaged endothelial cells, suggesting that Nalp3-dependent immune responses may play a role in the brain pathogenesis of CM <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7d</bold></xref> (ii)<bold>)</bold>. CD45 staining also shows infiltration of leukocytes in the brains of <italic>Plasmodium</italic> infected Nalp3<sup>&#x0002b;/&#x0002b;</sup> mice, whereas Nalp3<sup>&#x02212;/&#x02212;</sup> mice show reduced CD45 staining <bold>(</bold><xref ref-type="fig" rid="pone-0006510-g007"><bold>Figure 7d</bold></xref> (iii and iv)<bold>)</bold>.</p><fig id="pone-0006510-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006510.g007</object-id><label>Figure 7</label><caption><title>Role of Nalp3 in a mouse model of cerebral malaria.</title><p>(a-d) Nalp3-deficient mice have increased resistance to cerebral malaria (CM). (a, b) Survival of Nalp3<sup>&#x0002b;/&#x0002b;</sup> (solid line) and Nalp3<sup>&#x02212;/&#x02212;</sup> (dotted line) mice was monitored daily (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;18&#x02013;22 for each group, (&#x0002a;) log-rank p&#x0200a;&#x0003d;&#x0200a;0.0263) and parasitemia was assessed by blood smears (mean parasitemia&#x000b1;s.e.m., <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6 for each group, N3<sup>&#x0002b;/&#x0002b;</sup>&#x0200a;&#x0003d;&#x0200a;black square, N3<sup>&#x02212;/&#x02212;</sup>&#x0200a;&#x0003d;&#x0200a;open circles). (c) Nalp3<sup>&#x02212;/&#x02212;</sup>mice are protected from CM compared to Nalp3<sup>&#x0002b;/&#x0002b;</sup> mice (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;15 for each group). (d) Histological analysis of brain sections of Nalp3<sup>&#x0002b;/&#x0002b;</sup> (panel i and iii) and Nalp3<sup>&#x02212;/&#x02212;</sup> (panel ii and iv) mice 9 days after <italic>Plasmodium</italic> infection. Haematoxylin &#x00026; Eosin staining is shown in panels i and ii, CD45 staining is shown in panels iii and iv. Infected Nalp3<sup>&#x0002b;/&#x0002b;</sup> mice brains show pathological endothelial cells (open triangles) and lymphomonocytic infiltrates (closed triangles) whereas in the brains from infected Nalp3-deficient mice these pathological signs are markedly reduced (panels i and ii).</p></caption><graphic xlink:href="pone.0006510.g007"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>A better comprehension of the molecular mechanisms leading to malaria is instrumental for the development of novel and more efficient anti-malarial drugs. It is generally accepted that in addition to parasite-associated virulence factors, an exacerbated host inflammatory response to parasite infection resulting in collateral damage, contributes to cerebral malaria <xref ref-type="bibr" rid="pone.0006510-Langhorne1">&#x0005b;4&#x0005d;</xref>. TLRs are thought to play a central role in this response, since they are not only able to detect parasite-specific molecular patterns, but also host-derived hemozoin in a complex with plasmodial DNA <xref ref-type="bibr" rid="pone.0006510-Coban2">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Parroche1">&#x0005b;13&#x0005d;</xref>. Here we show that in addition to TLRs, hemozoin activates the Nalp3 inflammasome, thus possibly explaining its potent proinflammatory activity.</p><p>A plethora of Nalp3 inflammasome-activating substances have been identified. A minority of them are PAMPs of bacterial or viral origin, while most of them are host-derived substances or particles released into the environment (DAMPs). The most active known endogenous danger signals are ATP and MSU. Hemozoin appears to match the level of potency of these two activators. Unlike ATP that activates the Nalp3 inflammasome through P2X7 receptor-mediated K<sup>&#x0002b;</sup> efflux, hemozoin requires crystal formation (the precursor heme is inactive) in the same way as MSU, where soluble uric acid does not activate the inflammasome. It is therefore not surprising that hemozoin and MSU use similar signalling pathways, including crystal phagocytosis, generation of ROS and K<sup>&#x0002b;</sup> efflux.</p><p>The exact role which hemozoin plays in malaria pathogenesis is still a matter of debate. Although hemozoin was initially proposed to possess a direct neurotoxic role through activation of TLRs, murine cerebral malaria was recently shown to develop in the absence of TLR signalling <xref ref-type="bibr" rid="pone.0006510-Coban3">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006510-Togbe1">&#x0005b;12&#x0005d;</xref>. The obvious differences in these studies are not easily explained, as the experimental settings used are almost identical. Our results suggest that the Nalp3 inflammasome may also contribute to the effects of malaria and possibly also to the neurotoxicity. If future studies can confirm this notion, drugs that dampen hemozoin-triggered inflammasome activation may thus efficaciously complement conventional antimalarial drugs.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Mice</title><p><italic>Nalp3<sup>&#x02212;/&#x02212;</sup></italic><xref ref-type="bibr" rid="pone.0006510-Martinon2">&#x0005b;21&#x0005d;</xref>, <italic>Asc<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Ipaf<sup>&#x02212;/&#x02212;</sup></italic><xref ref-type="bibr" rid="pone.0006510-Mariathasan1">&#x0005b;23&#x0005d;</xref>, <italic>caspase-1<sup>&#x02212;/&#x02212;</sup></italic><xref ref-type="bibr" rid="pone.0006510-Kuida1">&#x0005b;24&#x0005d;</xref>, <italic>MyD88<sup>&#x02212;/&#x02212;</sup></italic><xref ref-type="bibr" rid="pone.0006510-Adachi1">&#x0005b;25&#x0005d;</xref>, gp91phox<sup>&#x02212;/&#x02212;</sup> (Jackson Laboratories, stock#002365) and <italic>P2X7<sup>&#x02212;/&#x02212;</sup></italic> (Jackson Laboratories, stock#005576) mice (on C57BL/6J background) and <italic>IL-1R<sup>&#x02212;/&#x02212;</sup></italic><xref ref-type="bibr" rid="pone.0006510-Labow1">&#x0005b;26&#x0005d;</xref> (on BALB/c background) were housed at the University of Lausanne following the Swiss Federal Veterinary Office guidelines. Six to ten week old C57Bl/6J-OlaHsd and BALB/c-OlaHsd mice were purchased from Harlan, The Netherlands.</p></sec><sec id="s4b"><title>Reagents</title><p>Hemozoin was prepared as described <xref ref-type="bibr" rid="pone.0006510-Jaramillo1">&#x0005b;9&#x0005d;</xref>. Briefly, hemin chloride (from Sigma BioChemika, &#x0003e; 98&#x00025; HPLC) was dissolved in degassed NaOH, the pH adjusted to 4.8 by addition of propionic acid and the solution left O/N at 70&#x000b0;C. The formed crystals were extensively washed in NaHCO<sub>3</sub> several times, alternated with water rinses. Finally the crystals were washed with H<sub>2</sub>O and methanol alternatively, before being dried over phosphorus pentoxide. The crystals were then weighed and dissolved at a concentration of 10 mg/ml in PBS.</p><p>Nigericin, uric acid, cytochalasin D and z-VAD-fmk were purchased from Sigma and DPI from Alexis. Ultrapure LPS was obtained from Invivogen. Anti-human cleaved IL-1&#x003b2; (2021L) was purchased from Cell Signaling, and anti-IL1&#x003b2; p35 is a sheep antibody made in the Tschopp laboratory. The antibody against mouse IL-1&#x003b2; was a gift from Roberto Solari, Glaxo. The antibody against mouse caspase-1 (p20) was a generous gift from Dr. Peter Vandenabeele (Ghent University). Cytokine and chemokine detection was performed with the Cytometric Beads Array (CBA) kits from BD Biosciences. All tissue culture reagents were bought from Invitrogen.</p></sec><sec id="s4c"><title>Generation of THP1 cells expressing shRNA</title><p>THP-1 stably expressing shNALP3, caspase-1, ASC and p22phox were obtained as previously described <xref ref-type="bibr" rid="pone.0006510-Dostert1">&#x0005b;27&#x0005d;</xref>.</p></sec><sec id="s4d"><title>Cell preparation</title><p>Bone-marrow macrophages were derived form tibia and femoral bone marrow cells as described elsewhere <xref ref-type="bibr" rid="pone.0006510-Didierlaurent1">&#x0005b;28&#x0005d;</xref>. Mouse macrophages were primed overnight with 250 ng/ml ultra-pure LPS (Invivogen) and cell culture medium was removed before stimulation for 6 h in Optimem.</p><p>For experiments, THP-1 were differentiated 3 hours with 0.5 &#x000b5;M PMA. Cell extracts and precipitated supernatants were analyzed by western blot and CBA.</p></sec><sec id="s4e"><title><italic>In vivo</italic> mouse peritonitis model</title><p>Peritonitis was induced by injection of 0.25 mg of hemozoin or 0.2 mg zymosan in 0.5 ml sterile PBS. After 6 h, mice were killed by CO<sub>2</sub> exposure and peritoneal cavities were washed with 6 ml of PBS. The lavage fluids were analysed for neutrophil influx by FACS (CD11b<sup>&#x0002b;</sup> Ly-6C<sup>&#x0002b;</sup> Ly-6G<sup>high</sup> F4/80<sup>&#x02212;</sup>). The following monoclonal antibodies were used: anti-CD11b (M1/70), anti-F4/80 (BM8) from ebioscience, anti-Ly-6C (AL-21) and anti-Ly-6G (1A8) from BD Biosciences. Samples were acquired on a FACSCanto (BD Biosciences) and analyzed by using the FLOWJO software (Tree Star).</p></sec><sec id="s4f"><title><italic>Plasmodium berghei</italic> ANKA infection</title><p>The <italic>P. berghei</italic> (ANKA strain) was maintained by alternating cyclic passage of the parasite in <italic>Anopheles stephensi</italic> mosquitoes and in BALB/c mice at the mosquito colony of the Department of Biochemistry, University of Lausanne. Sporozoites were collected by dissecting the mosquito salivary glands in DMEM 21 days after their infective blood meal. Each mouse was infected with 10 viable sporozoites by IV injection in the tail vein. After 5 days, infection of red blood cells (RBC) was monitored by microscopy of Giemsa-stained thin blood smears and used to calculate parasitemia (as &#x00025; of infected RBC). 6&#x02013;10 days after infection, susceptible mice started to develop symptoms of cerebral malaria (CM). Survival and signs of disease were monitored daily. Animals that showed neurological signs, such as convulsions, ataxia and paralysis, and died between 7 and 12 days after infection were considered to have CM. Brains were removed and used for histological analysis.</p></sec><sec id="s4g"><title>Cerebral histopathology</title><p>Brains were fixed in buffered formol for 12 hours and paraffin-embedded. Cerebral tissue sections (2 &#x000b5;m) were stained with hematoxylin and eosin (HE) or Prussian blue using standard procedures. CD45 staining was performed after antigen retrieval with a TRIS/EDTA pH 9 solution. CD45/Ly5 antibody was from BD Pharmingen (#550539).</p></sec><sec id="s4h"><title>Statistical analysis</title><p>Differences between groups were calculated using the unpaired t test (GraphPad Prism version 5.0). Differences were considered significant when p&#x02264;0.05.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0006510.s001"><label>Figure S1</label><caption><p>(4.82 MB TIF)</p></caption><media xlink:href="pone.0006510.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006510.s002"><label>Figure S2</label><caption><p>(1.14 MB TIF)</p></caption><media xlink:href="pone.0006510.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006510.s003"><label>Figure S3</label><caption><p>(1.33 MB TIF)</p></caption><media xlink:href="pone.0006510.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Drs. Emmanuelle Logette, Mirjam Eckert and Kate Schroder for helpful discussions and critical reading of the manuscript. We also thank Dr Vandenabeele for the generous gift of mouse anti-caspase 1 antibody and Marie-C&#x000e9;cile Michallet for the gift of cathepsin B<sup>&#x02212;/&#x02212;</sup> bone marrow.</p></ack><ref-list><title>References</title><ref id="pone.0006510-Silvie1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvie</surname><given-names>O</given-names></name><name><surname>Mota</surname><given-names>MM</given-names></name><name><surname>Matuschewski</surname><given-names>K</given-names></name><name><surname>Prudencio</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Interactions of the malaria parasite and its mammalian host.</article-title><source>Curr Opin Microbiol</source><volume>11</volume><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">18644249</pub-id></mixed-citation></ref><ref id="pone.0006510-Idro1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idro</surname><given-names>R</given-names></name><name><surname>Jenkins</surname><given-names>NE</given-names></name><name><surname>Newton</surname><given-names>CR</given-names></name></person-group><year>2005</year><article-title>Pathogenesis, clinical features, and neurological outcome of cerebral malaria.</article-title><source>Lancet Neurol</source><volume>4</volume><fpage>827</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">16297841</pub-id></mixed-citation></ref><ref id="pone.0006510-Beeson1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeson</surname><given-names>JG</given-names></name><name><surname>Osier</surname><given-names>FH</given-names></name><name><surname>Engwerda</surname><given-names>CR</given-names></name></person-group><year>2008</year><article-title>Recent insights into humoral and cellular immune responses against malaria.</article-title><source>Trends Parasitol</source><volume>24</volume><fpage>578</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">18848497</pub-id></mixed-citation></ref><ref id="pone.0006510-Langhorne1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langhorne</surname><given-names>J</given-names></name><name><surname>Ndungu</surname><given-names>FM</given-names></name><name><surname>Sponaas</surname><given-names>AM</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name></person-group><year>2008</year><article-title>Immunity to malaria: more questions than answers.</article-title><source>Nat Immunol</source><volume>9</volume><fpage>725</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">18563083</pub-id></mixed-citation></ref><ref id="pone.0006510-Schofield1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schofield</surname><given-names>L</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name></person-group><year>2005</year><article-title>Immunological processes in malaria pathogenesis.</article-title><source>Nat Rev Immunol</source><volume>5</volume><fpage>722</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">16138104</pub-id></mixed-citation></ref><ref id="pone.0006510-Coban1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coban</surname><given-names>C</given-names></name><name><surname>Ishii</surname><given-names>KJ</given-names></name><name><surname>Horii</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Manipulation of host innate immune responses by the malaria parasite.</article-title><source>Trends Microbiol</source><volume>15</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">17466521</pub-id></mixed-citation></ref><ref id="pone.0006510-Egan1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>TJ</given-names></name></person-group><year>2008</year><article-title>Haemozoin formation.</article-title><source>Mol Biochem Parasitol</source><volume>157</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">18083247</pub-id></mixed-citation></ref><ref id="pone.0006510-Hanscheid1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanscheid</surname><given-names>T</given-names></name><name><surname>Egan</surname><given-names>TJ</given-names></name><name><surname>Grobusch</surname><given-names>MP</given-names></name></person-group><year>2007</year><article-title>Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator.</article-title><source>Lancet Infect Dis</source><volume>7</volume><fpage>675</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">17897610</pub-id></mixed-citation></ref><ref id="pone.0006510-Jaramillo1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaramillo</surname><given-names>M</given-names></name><name><surname>Plante</surname><given-names>I</given-names></name><name><surname>Ouellet</surname><given-names>N</given-names></name><name><surname>Vandal</surname><given-names>K</given-names></name><name><surname>Tessier</surname><given-names>PA</given-names></name><etal/></person-group><year>2004</year><article-title>Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection.</article-title><source>J Immunol</source><volume>172</volume><fpage>3101</fpage><lpage>3110</lpage><pub-id pub-id-type="pmid">14978116</pub-id></mixed-citation></ref><ref id="pone.0006510-Coban2"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coban</surname><given-names>C</given-names></name><name><surname>Ishii</surname><given-names>KJ</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin.</article-title><source>J Exp Med</source><volume>201</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15630134</pub-id></mixed-citation></ref><ref id="pone.0006510-Coban3"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coban</surname><given-names>C</given-names></name><name><surname>Ishii</surname><given-names>KJ</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Arisue</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Pathological role of Toll-like receptor signaling in cerebral malaria.</article-title><source>Int Immunol</source><volume>19</volume><fpage>67</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">17135446</pub-id></mixed-citation></ref><ref id="pone.0006510-Togbe1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togbe</surname><given-names>D</given-names></name><name><surname>Schofield</surname><given-names>L</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name><name><surname>Schnyder</surname><given-names>B</given-names></name><name><surname>Boissay</surname><given-names>V</given-names></name><etal/></person-group><year>2007</year><article-title>Murine cerebral malaria development is independent of toll-like receptor signaling.</article-title><source>Am J Pathol</source><volume>170</volume><fpage>1640</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">17456769</pub-id></mixed-citation></ref><ref id="pone.0006510-Parroche1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parroche</surname><given-names>P</given-names></name><name><surname>Lauw</surname><given-names>FN</given-names></name><name><surname>Goutagny</surname><given-names>N</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Monks</surname><given-names>BG</given-names></name><etal/></person-group><year>2007</year><article-title>Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9.</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>1919</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">17261807</pub-id></mixed-citation></ref><ref id="pone.0006510-Martinon1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.</article-title><source>Mol Cell</source><volume>10</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">12191486</pub-id></mixed-citation></ref><ref id="pone.0006510-Shaw1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>MH</given-names></name><name><surname>Reimer</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>NOD-like receptors (NLRs): bona fide intracellular microbial sensors.</article-title><source>Curr Opin Immunol</source><volume>20</volume><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">18585455</pub-id></mixed-citation></ref><ref id="pone.0006510-Yu1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>HB</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group><year>2008</year><article-title>The caspase-1 inflammasome: a pilot of innate immune responses.</article-title><source>Cell Host Microbe</source><volume>4</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">18779046</pub-id></mixed-citation></ref><ref id="pone.0006510-Sutterwala1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutterwala</surname><given-names>FS</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year>2008</year><article-title>NLRC4/IPAF: a CARD carrying member of the NLR family.</article-title><source>Clin Immunol</source></mixed-citation></ref><ref id="pone.0006510-Weissbuch1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissbuch</surname><given-names>I</given-names></name><name><surname>Leiserowitz</surname><given-names>L</given-names></name></person-group><year>2008</year><article-title>Interplay between malaria, crystalline hemozoin formation, and antimalarial drug action and design.</article-title><source>Chem Rev</source><volume>108</volume><fpage>4899</fpage><lpage>4914</lpage><pub-id pub-id-type="pmid">19006402</pub-id></mixed-citation></ref><ref id="pone.0006510-Macfarlane1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macfarlane</surname><given-names>DE</given-names></name><name><surname>Manzel</surname><given-names>L</given-names></name></person-group><year>1998</year><article-title>Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.</article-title><source>J Immunol</source><volume>160</volume><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">9570525</pub-id></mixed-citation></ref><ref id="pone.0006510-Hornung1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Bauernfeind</surname><given-names>F</given-names></name><name><surname>Halle</surname><given-names>A</given-names></name><name><surname>Samstad</surname><given-names>EO</given-names></name><name><surname>Kono</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.</article-title><source>Nat Immunol</source><volume>9</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">18604214</pub-id></mixed-citation></ref><ref id="pone.0006510-Martinon2"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Petrilli</surname><given-names>V</given-names></name><name><surname>Mayor</surname><given-names>A</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome.</article-title><source>Nature</source><volume>440</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16407889</pub-id></mixed-citation></ref><ref id="pone.0006510-Sanni1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanni</surname><given-names>LA</given-names></name><name><surname>Fonseca</surname><given-names>LF</given-names></name><name><surname>Langhorne</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Mouse models for erythrocytic-stage malaria.</article-title><source>Methods Mol Med</source><volume>72</volume><fpage>57</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12125155</pub-id></mixed-citation></ref><ref id="pone.0006510-Mariathasan1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name><name><surname>French</surname><given-names>DM</given-names></name><etal/></person-group><year>2004</year><article-title>Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf.</article-title><source>Nature</source><volume>430</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">15190255</pub-id></mixed-citation></ref><ref id="pone.0006510-Kuida1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuida</surname><given-names>K</given-names></name><name><surname>Lippke</surname><given-names>JA</given-names></name><name><surname>Ku</surname><given-names>G</given-names></name><name><surname>Harding</surname><given-names>MW</given-names></name><name><surname>Livingston</surname><given-names>DJ</given-names></name><etal/></person-group><year>1995</year><article-title>Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme.</article-title><source>Science</source><volume>267</volume><fpage>2000</fpage><lpage>2003</lpage><pub-id pub-id-type="pmid">7535475</pub-id></mixed-citation></ref><ref id="pone.0006510-Adachi1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>O</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><etal/></person-group><year>1998</year><article-title>Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.</article-title><source>Immunity</source><volume>9</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">9697844</pub-id></mixed-citation></ref><ref id="pone.0006510-Labow1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labow</surname><given-names>M</given-names></name><name><surname>Shuster</surname><given-names>D</given-names></name><name><surname>Zetterstrom</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>P</given-names></name><name><surname>Terry</surname><given-names>R</given-names></name><etal/></person-group><year>1997</year><article-title>Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice.</article-title><source>J Immunol</source><volume>159</volume><fpage>2452</fpage><lpage>2461</lpage><pub-id pub-id-type="pmid">9278338</pub-id></mixed-citation></ref><ref id="pone.0006510-Dostert1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostert</surname><given-names>C</given-names></name><name><surname>Petrilli</surname><given-names>V</given-names></name><name><surname>Van Bruggen</surname><given-names>R</given-names></name><name><surname>Steele</surname><given-names>C</given-names></name><name><surname>Mossman</surname><given-names>BT</given-names></name><etal/></person-group><year>2008</year><article-title>Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.</article-title><source>Science</source><volume>320</volume><fpage>674</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">18403674</pub-id></mixed-citation></ref><ref id="pone.0006510-Didierlaurent1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didierlaurent</surname><given-names>A</given-names></name><name><surname>Brissoni</surname><given-names>B</given-names></name><name><surname>Velin</surname><given-names>D</given-names></name><name><surname>Aebi</surname><given-names>N</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide.</article-title><source>Mol Cell Biol</source><volume>26</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">16428431</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from Mugen and Hermione EU grants. CD is supported by an EMBO long-term fellowship, PM is supported by the Swiss National Science Foundation through a MD-PhD grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>